Nymox stock rises 8% as it files for FDA approval of drug treating enlarged prostate

Grandbrothers/iStock Editorial via Getty Images

• Nymox Pharmaceutical (NYMX +7.8%) submitted a new drug application (NDA) to the FDA for Fexapotide Triflutate to treat men with benign prostatic hyperplasia (BPH).
• BPH also called prostate gland enlargement can cause uncomfortable urinary symptoms and can also cause bladder, urinary tract or kidney problems.
• The company said it intends to submit applications in other major markets in the near term.
• In the past year, the company had struggled with the filing of the NDA and had faced several delays.

Comments

[sidnal5]

Competition has arisen from focused ultra sound.

[Stan Piland]

@sidnal5 Technically challenging, expensive, invasive, painful, and requires anesthesia. No chance any patient or doc would choose HIFU before FT.

[Stan Piland]

Finally! This is a transformative drug for treatment of enlarged prostate, can easily be a $10B+ drug once approved in all markets.

[coffeedoc1]

@Stan Piland Hopefully they can stay out of their own way and find a good experienced partner to help bring this to market.

[Stan Piland]

@coffeedoc1 Agreed! Estimated 8.5M actively managed patients in the US and 13M in Europe. Plus 60M in APAC, which isn't in my estimates. Other drugs are all off patent, so I don't think they would have much trouble finding a partner. Also, FT is really inexpensive to manufacture, so they could likely get a very generous royalty.